IMV is re-establishing its facility in the market under the prospectus of the revamped base rack

Article content

Dartmouth, Nova Scotia, and Cambridge, Massachusetts – IMV Inc. (“IMV“or the”a company‘) (Nasdaq: IMV; TSX: IMV), a clinical-stage company that is developing a range of immunoculture therapies based on its novel DPX® A platform for treating solid cancers and hematology, today announced that it plans to maintain its existing facility in the market which was initially announced on October 16, 2020 under a recently revamped basic shelf prospectus, effective for a period of 25 months effective July 25, 2022. IMV has entered into an agreement distribution of property rights (“EDA‘) dated August 4, 2022 with Piper Sandler & Co. (“)Piper Sandler“) under which the Company may sell from time to time through “in the market” offers (“Automated teller machine‘), with Piper Sandler serving as a sales agent, on the Nasdaq capital market (“Nasdaq”) Number of Ordinary Shares with a total offering price of US$50 million under the ATM Prospectus Supplement (as defined below).

Ad 2

Article content

The ATM offer will be made by way of an appendix to the prospectus (“ATM Bulletin Supplement“) to the Company’s final Canadian prospectus dated July 22, 2022, and the Company’s final US prospectus which is contained in the Company’s US registration statement on Form F-10 dated July 25, 2022, as amended (File No. 333-266082). ) (“Registration statement“). The registration statement was in effect when it was filed with the US Securities and Exchange Commission (“).SEC”) on July 25, 2022. An appendix to the ATM prospectus was filed with the Nova Scotia Securities Commission, as the primary regulator in Canada, and in the United States with the Securities and Exchange Commission. Conditionally approved for the listing of common stock that the company may issue through View ATMs on the Toronto Stock Exchange (“TSXRequired notices related to the ATM offering have also been submitted to NASDAQ. In obtaining approval for the TSX listing, the company relied on the exemption of a “qualified joint issuer” from the TSX rules under Section 602.1 of the TSX Company Manual.

Piper Sandler will, at IMV’s discretion and instructions, use its commercially reasonable efforts to sell common stock at market prices from time to time. No offers or sales of the Ordinary Shares will be made in Canada or through the facilities of TSX or any other trading market in Canada.

The Company plans to use the net proceeds from the ATM offering for general corporate purposes, including but not limited to working capital expenditures, capital expenditures, research and development expenditures, and clinical trial expenditures.

Copies of the ATM Prospectus and the accompanying Final Basic Rack Prospectus relating to the offered common stock may be obtained free of charge from the offices of Piper Sandler & Co. By phone at (800) 747-3924 or via email at

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, and there shall be no sale of such common stock in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualifications under the securities laws of any such jurisdiction.

About IMV

IMV Inc. is a clinical-stage immuno-oncology company that develops a range of treatments based on the company’s immuno-education platform, DPX.®.

Advertising 3

Article content

IMV’s forward-looking statements

This press release contains forward-looking information under applicable securities law. All information regarding activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements use words such as “will,” “may,” “probable,” “believe,” “expect,” “continue,” “expect” and other similar terms. Forward-looking statements are based on management’s estimates and opinions at the date the statements were made. In the press release, these forward-looking statements include, but are not limited to, statements about potential sales of common stock, statements regarding how the company intends to use proceeds from the sale of common stock, statements regarding the valuation and development of MVP-S and DPX-SurMAGE, and the company’s ability to: Develop its development strategy, as well as prospects for major immunotherapy and other pipelines of immunotherapy candidates. However, such statements should not be taken as a representation that any of the plans will be realized. Actual results may differ materially from those stated in this press release due to risks affecting the Company, including access to capital, successful design, completion of clinical trials, and receipt of all regulatory approvals in time to commence and then continue clinical studies. experiments and receiving all regulatory approvals for marketing its products. IMV assumes no responsibility to update the forward-looking statements contained in this press release except as required by law. These forward-looking statements involve known and unknown risks and uncertainties, and such risks and uncertainties include, but are not limited to, the Company’s ability to successfully sell common stock in the proposed offering; The expected schedule of the company associated with its cash path; The Company’s priorities with MVP-S and DPX-SurMAGE, platform availability and expected timing of enrollment and outcomes for its clinical trial programs and studies, and other risks detailed from time to time in the Company’s ongoing quarterly filings and current annual information form. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV’s continuing disclosure documents, including the current annual information form, as well as audited annual consolidated financial statements available on SEDAR at and on EDGAR at www.sec. gov/edgar.

View source version on



Investor Relations

Irina Kofler, General Manager, LifeSci Advisors
O: (646) 970-4681
M: (917) 734-7387

The media

Delphine Davan, Senior Director, Communications and Investor Relations, IMV Inc.
M: (514) 968 1046

Madeleine Joannis, Senior Account Manager, LifeSci Communications
M: (603) 479 5267

# distro

Ad 1


Postmedia is committed to maintaining an active and civil forum for discussion and encouraging all readers to share their opinions on our articles. Comments may take up to an hour to be moderated before they appear on the Site. We ask that you keep your comments relevant and respectful. We’ve enabled email notifications – you’ll now receive an email if you get a response to your comment, if there’s an update to a comment thread you’re following or if it’s a comment follower user. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Leave a Comment